P
Pascal Do
Publications - 33
Citations - 1103
Pascal Do is an academic researcher. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 14, co-authored 32 publications receiving 855 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel,Julien Mazieres,Laurent Greillier,Sylvie Lantuejoul,Pascal Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Florian Guisier,Thierry Urban,Catherine Ligeza-poisson,David Planchard,E. Amour,Franck Morin,Denis Moro-Sibilot,Gérard Zalcman,Didier Debieuvre,Sandrine Hiret,Jacques Cadranel,Séverine Fraboulet-Moreau,Delphine Carmier +23 more
TL;DR: This multicentre randomised, non-comparative, open-label, phase 2 trial aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
Christos Chouaid,Cécile Dujon,Pascal Do,Isabelle Monnet,A. Madroszyk,Hervé Le Caer,Jean Bernard Auliac,Henri Berard,Pascal Thomas,Hervé Lena,Gilles Robinet,N. Baize,Acya Bizieux-Thaminy,G. Fraboulet,Chrystele Locher,Jacques Le Treut,S. Hominal,Alain Vergnenegre +17 more
TL;DR: Re-biopsy of advanced NSCLC is feasible in the real-world setting, with acceptable adverse events, and guidelines are needed on the indications of re-biops, the choice of procedure, the sampling site, and laboratory analysis.
Journal ArticleDOI
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
Charline Lasnon,Cédric Desmonts,Elske Quak,Radj Gervais,Pascal Do,Catherine Dubos-Arvis,Nicolas Aide +6 more
TL;DR: Protocol-optimized images and compliance with EANM guidelines allowed for a reliable pre- and post-therapy evaluation when using different generation PET systems and these data obtained in NSCLC patients could be extrapolated to other solid tumours.
Journal ArticleDOI
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Sébastien Couraud,Pierre-Jean Souquet,Christophe Paris,Pascal Do,Hélène Doubre,Eric Pichon,Adrien Dixmier,Isabelle Monnet,Bénédicte Etienne-Mastroianni,Michel Vincent,Jean Trédaniel,Marielle Perrichon,Pascal Foucher,Benoit Coudert,Denis Moro-Sibilot,Eric Dansin,Stéphanie Labonne,P. Missy,Franck Morin,Hélène Blanché,Gérard Zalcman +20 more
TL;DR: The largest and most comprehensive LCINS analysis in a European population is presented and Physicians should track occupational exposure in men (35%), and a somatic molecular alteration in both sexes (73%) in lung cancer of European never-smokers.
Journal ArticleDOI
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
Arnaud Scherpereel,Julien Mazieres,Laurent Greillier,Pascal Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Luc Thiberville,Thierry Urban,Catherine Ligeza-poisson,David Planchard,E. Amour,Franck Morin,Denis Moro-Sibilot,Gérard Zalcman +17 more
TL;DR: Primary endpoint was DCR at 12 weeks with a blinded independent central review (BICR), and patients were to be randomized with one-step Fleming procedure, H0 P 40%, with 95% powe...